You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
NamePotassium Iodide
Accession NumberDB06715
TypeSmall Molecule

Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperglycemia (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy.

KaliumiodidNot AvailableNot Available
KINot AvailableNot Available
Potassium iodideNot AvailableNot Available
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Thyrosafetablet65 mgoralRecip Ab2003-11-042008-07-07Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Iosattablet130 mgoralAnbex Inc.1982-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Iosattablet65 mgoralAnbex Inc.2013-05-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Thyroblock Tab 130mgtablet130 mgoralCarter Horner Corp.1981-12-312003-03-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Thyroshieldsolution65 mg/mLoralFleming & Company, Pharmaceuticals2005-04-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Thyroshieldsolution65 mg/mLoralArco Pharmaceuticals LLC2014-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
International BrandsNot Available
Brand mixtures
DiodineProduits Marc O (1987) Inc., Division Of Technilab Inc.
Humco Strong Iodine TinctureHumo Holding Group, Inc.
Iodine Tct 2.5% BPStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Iodine Tct 5% CfStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Iodine Tincture 21/2%Ingram And Bell Inc.
Mathieu Cough SyrupJ L Mathieu Cie Ltee
MetrateMedic Laboratory LtÉe
Tincture Of IodineLawton's Drug Stores Ltd.
Tincture Of Iodine 2.5%D.C. Labs Limited
Tincture Of Iodine 5%D.C. Labs Limited
Vito Bronches SiropDuchesnay Inc
SaltsNot Available
CategoriesNot Available
CAS number7681-11-0
WeightAverage: 166.0028
Monoisotopic: 165.868175281
Chemical FormulaIK
potassium iodide
DescriptionThis compound belongs to the class of inorganic compounds known as alkali metal iodides. These are inorganic compounds in which the largest halogen atom is Iodine, and the heaviest metal atom is an alkali metal.
KingdomInorganic compounds
Super ClassMixed metal/non-metal compounds
ClassAlkali metal salts
Sub ClassAlkali metal iodides
Direct ParentAlkali metal iodides
Alternative Parents
  • Alkali metal iodide
  • Inorganic salt
  • Acyclic compound
Molecular FrameworkAcyclic compounds
External Descriptors
IndicationPotassium Iodide is oral antithyroid agent. Potassium Iodide is used as an adjunct to other antithyroid agents in the treatment of hyperthyroidism and thyrotoxicosis and preoperatively to induce thyroid involution.
PharmacodynamicsIt works in the thyroid gland. By inhibiting thyroid hormone synthesis and release, thyroid gland vascularity is reduced, thyroid gland tissue becomes firmer, thyroid cell size is reduced, follicular colloid reaccumulates, and bound iodine levels increase. As a protectant following radiation exposure, KI blocks the uptake of radioactive iodine isotopes by the thyroid gland thereby minimizing the risk of radiation-induced thyroid neoplasms.
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Predicted ADMET features
Human Intestinal Absorption+0.7647
Blood Brain Barrier+0.9702
Caco-2 permeable+0.6625
P-glycoprotein substrateNon-substrate0.8989
P-glycoprotein inhibitor INon-inhibitor0.984
P-glycoprotein inhibitor IINon-inhibitor0.9854
Renal organic cation transporterNon-inhibitor0.9282
CYP450 2C9 substrateNon-substrate0.8261
CYP450 2D6 substrateNon-substrate0.7789
CYP450 3A4 substrateNon-substrate0.7857
CYP450 1A2 substrateNon-inhibitor0.7164
CYP450 2C9 inhibitorNon-inhibitor0.8527
CYP450 2D6 inhibitorNon-inhibitor0.9142
CYP450 2C19 inhibitorNon-inhibitor0.8842
CYP450 3A4 inhibitorNon-inhibitor0.9317
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9022
Ames testNon AMES toxic0.6838
CarcinogenicityCarcinogens 0.659
BiodegradationNot ready biodegradable0.5913
Rat acute toxicity2.9202 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9535
hERG inhibition (predictor II)Non-inhibitor0.9657
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
ManufacturersNot Available
PackagersNot Available
Dosage forms
Liquidtopical750 mg
Liquidtopical70; 50; 850 mg/mL; mg/mL; mg/mL
Tincturetopical25 mg
Tincturetopical50 mg
Tincturetopical2.5 %
Tabletoral130 mg
Tabletoral65 mg
Syruporal4.2 mg
Syruporal5 mg
Solutionoral65 mg/mL
Liquidtopical2.5 %
Liquidtopical5 %
PricesNot Available
PatentsNot Available
Experimental PropertiesNot Available
Predicted Properties
Physiological Charge1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Mass Spec (NIST)Not Available
SpectraNot Available
Synthesis Reference

Stanley D. Lazarus, “Production of thermally stabilized polyester with alkylene carbonates and sodium or potassium iodide.” U.S. Patent US4327207, issued October, 1973.

General ReferencesNot Available
External Links
ATC CodesR05CA02S01XA04V03AB21
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Drug Interactions
AliskirenPotassium Salts may enhance the hyperkalemic effect of Aliskiren.
EplerenoneMay enhance the hyperkalemic effect of Potassium Salts.
HeparinMay enhance the hyperkalemic effect of Potassium Salts.
LithiumPotassium Iodide may enhance the hypothyroid effect of Lithium.
Food InteractionsNot Available


1. Tyrosine

Kind: small molecule

Organism: Human

Pharmacological action: unknown

Actions: binder


Name UniProt ID Details


  1. Pisarev MA, Aiello LO: Studies on the mechanism of action of potassium iodide on thyroid protein biosynthesis. Acta Endocrinol (Copenh). 1976 Jun;82(2):298-305. Pubmed
  2. Foldes J, Gesztesi E, Juhasz J: Mechanism of action of di-iodotyrosine and of iodine. Acta Med Acad Sci Hung. 1974;31(1-2):131-7. Pubmed

comments powered by Disqus
Drug created on May 16, 2010 17:39 /Updated on September 16, 2013 18:04